Diabetic nephropathy remains a leading cause of endstage renal disease (ESRD) in western societies, accounting for about 40% of all patients beginning renal replacement therapy. Patients with type 2 diabetes comprise the largest and fastest growing single disease group requiring renal replacement therapy. In addition to the high risk of progression to ESRD, diabetic nephropathy is associated with a very high risk of cardiovascular (CV) morbidity and mortality, which is not abolished by dialysis or renal transplantation. Over the past two decades there have been major advances in our attempts to understand the risk factors for development and progression of diabetic renal dysfunction, that have resulted in better characterisation of the natural history of this serious complication. Effective antihypertensive treatment and aggressive management of CV risk factors have helped improve the prognosis of patients with overt diabetic nephropathy, particularly those with type 1 diabetes. However, for the larger proportion of patients with type 2 diabetes, the renal and CV prognoses are still poor. Recently, more focus has been placed on treating diabetic patients early in order to prevent future organ damage. Microalbuminuria is an
Introduction
Diabetic nephropathy (DN) remains a leading cause of end-stage renal disease (ESRD) in western societies. Diabetes is the single largest cause of ESRD in American and European adults, accounting for over one-third of all patients enrolling onto renal support therapy programmes.
1,2 Approximately 50-60% of patients with diabetic nephropathy have type 2 diabetes. Indeed because of the increasing prevalence of type 2 diabetes and the longer survival of patients, they now comprise the largest and fastest growing single disease group requiring renal replacement therapy in the general population.
Diabetic nephropathy is conventionally defined as important intermediary end-point that correlates strongly with CV mortality in all people with diabetes as well as progression to ESRD in people with type 1 diabetes. We can now identify patients at high risk early in the natural history of their disease. Clinical trials have uniformly shown that in the early disease history of diabetes, achievement of both tight glucose control, eg, HbA1c Ͻ7%, and tight blood pressure control eg, blood pressure Ͻ140/80 mm Hg, substantially reduces CV events and progression of nephropathy. In latter stages of diabetes, tight blood pressure control has a relatively greater impact on CV risk reduction as compared to tight glucose control. The challenge for the practising physician, however, is to maximally utilise the available modalities of treatment to prevent progression to overt nephropathy and reduce the associated high risk of CV morbidity and mortality. In the early 21st century, the patient with type 2 diabetes will need to be the specific focus for use of these preventive treatment modalities due to the geometric risk in the international incidence of this disease.
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the clinical syndrome characterised by persistent albuminuria (Ͼ300 mg/24 h or Ͼ200 g/min), detected on two or more occasions over a period of several months. Patients invariably demonstrate associated hypertension, a predictable and relentless decline in glomerular filtration rate (GFR) and a progressive increase in proteinuria. 3 In this review article, we shall concentrate on the importance of early detection of nephropathy and the role of available treatment modalities to improve renal and cardiovascular outcomes.
Epidemiology
The cumulative incidence of nephropathy appears to be similar in both type 1 and type 2 diabetes. 4, 5 Traditionally, nephropathy occurs in 30-40% of patients with type 1 diabetes. The majority of these patients will, without specific intervention, develop ESRD within 10-15 years from the onset of overt DN.
Population-based studies indicate a prevalence of nephropathy of 5-10% at diagnosis of type 2 diabetes, probably reflecting the prolonged period of sub-clinical hyperglycaemia. Similar studies have documented a cumulative incidence of overt DN of 25-60% at 20 years of type 2 diabetes, depending on racial origin. 8 Type 2 diabetes is between 10-15 times more common than type 1 diabetes in Europe and North American populations, making the prevalence of nephropathy due to type 2 diabetes higher. However, the greater risk of dying from associated cardiovascular disease in the older population with type 2 diabetes may prevent many with earlier stages of overt DN from progressing to ESRD. As prevention and treatment of cardiovascular disease continue to improve, however, more patients with type 2 diabetes may be expected to survive long enough to develop ESRD.
Ethnic differences in diabetes-related renal disease
The incidence of diabetes in those with newly diagnosed ESRD varies widely depending on the ethnic origin of the population. Studies of Pima Indians show a cumulative incidence of ESRD of 40% at 10 years and 61% at 15 years following the onset of proteinuria. 9 For diabetes related ESRD, Mexican Americans have an incidence ratio of 6, while African Americans have a ratio of 4 when compared to Caucasian populations. 10 In a Michigan-based study the incidence of diabetic ESRD was 2.6-fold higher among African Americans, with the excess risk occurring predominantly in the type 2 diabetic population; most of these patients with ESRD had type 2 diabetes, whereas most white patients had type 1 diabetes. 11 The incidence of ESRD is also significantly raised among Indo-Asians and Afro-Caribbean populations within the UK. Indeed, type 2 diabetic patients of Indo-Asian and Afro-Caribbean origins have three-to four-fold higher acceptance rates on to renal replacement programmes than Caucasians within the UK. 12 The causes of these ethnic differences in incidence of renal disease from type 2 are multi-factorial. Diabetes and hypertension are much more prevalent among the Asian and Afro-Caribbean than the Caucasian population. Although there is an increased incidence of ESRD due to diabetes, there is also an increased incidence of glomerulonephritis and chronic pyelonephritis, with a five-fold increase in ESRD of uncertain cause associated with nonrenal tuberculosis (TB) suggesting a generalised increased susceptibility to renal disease 12 (Table 1) . In Native American patients with type 2 diabetes, those who become hypertensive after the diagnosis of diabetes are more likely to develop nephropathy as compared to those subjects whose hypertension was diagnosed prior to diabetes. In the Caucasian population, hypertension does not uniformly herald a subsequent decline in renal function. Certain ethnic groups such as the Pima Indians have an especially high incidence of nephropathy. In such patient populations, a strong familial clustering of nephropathy has also been reported; 14.3% of diabetic offspring if neither parent had proteinuria, 22.9% if at least one parent had proteinuria and 45.9% if both parents had nephropathy.
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Morbidity and mortality associated with diabetic renal dysfunction
In the pre-dialysis era, follow-up studies in the UK 14 and Denmark 15 of 134 and 101 type 1 diabetic patients, respectively, demonstrated survival rates of 50% and approximately 40% at 10 years. Studies from the Joslin clinic over the same period showed an approximately 17-fold increase in renal and cardiovascular death over the non-diabetic population. 16 Recently the WHO study of type 1 and type 2 patients found all-cause mortality ratios of 2.9 and 2.8, respectively, for those with heavy proteinuria after a mean follow-up of 9.4 years. 17 Studying a cohort of 2930 patients with type 1 diabetes, Danish workers demonstrated a 100-fold excess mortality for females and 80-fold for males with clinical nephropathy at the age of 40 compared to the nondiabetic background population. 18 Microalbuminuria has also been shown to be an independent predictor of mortality in type 2, and possibly type 1, diabetic patients compared to normoalbuminuric diabetic controls. Studies in type 2 diabetic patients found hazard ratios for mortality of approximately 1.5-2.3 in microalbuminuric patients after 10 years, with survival rates of approximately 30-40% compared to 55-60% in the normoalbuminuric patients. 19, 20 A recent large prospective observational study in 939 adults with type 1 diabetes followed up for an average of 10 years demonstrated that microalbuminuria was an independent significant predictor of all-cause (relative risk (RR) 1.45; confidence interval (CI) 1.18-1.77) and cardiovascular mortality (RR 1.87; CI 1.03-2.40) compared with the normoalbuminuric state. 21 Most of these excess deaths in patients were due to cardiovascular causes rather than renal failure.
The reasons for this excess mortality are not fully understood, but patients with renal dysfunction tend to have a clustering of cardiovascular risk factors including hypertension, smoking, hyperlipidaemia, endothelial dysfunction and increased fibrinogen/platelets aggregability [22] [23] [24] ( Figure 1 ). In those with microalbuminuria there is also a higher prevalence of insulin resistance, poor glycaemic control, left ventricular hypertrophy, proliferative retinopathy, neuropathy, peripheral vascular disease and foot ulcers. The prevalence of proliferative retinopathy and blindness increases with progressive albuminuria. Peripheral neuropathy, and with it the risk of foot ulceration, also increases with a prevalence of 21% in normoalbuminuria, 31% in microalbuminuria and 50% in those with macroalbuminuria 25 (Table 2) . Survival rates for patients with overt diabetic nephropathy appear to be improving, at least for patients with type 1 diabetes. After 10 years of persistent proteinuria, survival is now approximately 80% compared to 25% in the 1950s. 26 This dramatic improvement is attributed mainly to better control of hypertension and cardiovascular risk factors. However, for the much greater number of type 2 patients, the prevention of nephropathy and thus premature cardiovascular and renal deaths remains a major challenge for clinical medicine. 
Type 1 diabetes
The natural history of renal involvement has been better defined in type 1 than in type 2 diabetes. The pioneering work of Mogensen 27 has identified five distinct stages of renal dysfunction. The first stage relates to renal hypertrophy and hyperfiltration at the time of diagnosis of type 1 diabetes. GFR is elevated, as is urinary albumin excretion rate (UAER). GFR is elevated by 20 to 40% compared to agematched controls. The renal plasma flow is also elevated by between 9 and 14%. Institution of insulin therapy produces a reduction in both the GFR and UAER. Stage 2 occurs during average glycaemic control with conventional insulin therapy regimens and lasts for 5-15 years. During this 'silent phase', the GFR remains elevated ('hyperfiltration'), with normal UAER and blood pressure levels. Detailed renal morphometric studies during this phase, however, have demonstrated early histological changes including a non-specific increase in basement membrane thickness and fractional mesangial volume after 2-4 years. The 'hyperfiltration' is related to the degree of hyperglycaemia up to 14 mmol/l. Levels of glycaemia higher than this are associated with a reduction in GFR. The aetiological role of 'hyperfiltration' in the development of progressive renal dysfunction remains debatable. Data have been reported both supporting and refuting the hypothesis of hyperfiltration contributing to the initiation and progression of eventual renal dysfunction. Furthermore, improvement in glycaemic control during the second stage will invariably reduce the extent of hyperfiltration.
Stage 3, described as incipient nephropathy, occurs usually after 6-15 years of diabetes. UAER during this stage is 20-200 g/min (30-300 mg/24 h). The development of microalbuminuria is associated with a small but detectable increase in blood pressure, whilst still within the conventional age corrected normal ranges. A higher prevalence of impairment of the normal nocturnal 'dipping' of blood pressure on 24-h ambulatory blood pressure monitoring has also been reported. There is also further progression of the histological changes, with increases in basement membrane thickness and fractional mesangial volumes within the glomerulus, which will ultimately impinge on the filtration surfaces. Therefore, many claim this as a phase of early-established renal dysfunction. However, in type 2 diabetes such structural changes are not found in most patients at this stage. 28 The GFR may still be elevated or reduced into normal range. Generally, the decline in GFR is the same as age-matched controls until the development of overt DN.
Stage 3 is invariably followed by stage 4 of established or overt nephropathy. By now UAER is Ͼ200 g/min (or Ͼ300 mg/24 h), hypertension is established and there are clear histological changes. Albuminuria increases at the rate of 15-40% per annum. The GFR commence its relentless inexorable decline at a rate that is highly variable from individual to individual (2-20 ml/min/year). The rate of decline in GFR is strongly correlated with blood pressure levels, and without intervention ESRD (stage 5) develops in 50% of type 1 patients within 10 years and in 75% by 20 years following the onset of overt nephropathy.
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Type 2 diabetes
Information on the natural history of renal dysfunction in the type 2 diabetic patients group is relatively limited. Available data, however, would suggest similarities with the type 1 diabetic patients. Initially it was thought that hyperfiltration was confined to type 1 patients. Comparatively recent studies have reported 'hyperfiltration' in many newly diagnosed type 2 patients compared with agematched non-diabetic control, with reversion towards normal following treatment. Thirty to 40% of newly diagnosed type 2 patients demonstrated GFRs in excess of mean +2 s.d. of the controls. GFR values were unrelated to blood pressure, prevailing glycaemic parameters or lipid levels. The effective renal plasma flow (ERPF) was not raised in such patients, thus the filtration fraction (FF), calculated from GFR divided by ERPF, was also elevated in these patients. 30 The increased filtration fraction implies an elevation in the glomerular capillary pressure, thought to be an important factor in the development and progression of diabetic renal disease.
Initial therapy with consequent improvements in glycaemic control leads to a decrease in GFR. 31 These changes are witnessed predominantly in the younger type 2 patients. Cross-sectionally, a persistent elevation is evident in 25% of the younger type 2 patients. Subsequent follow-up for 2 years demonstrates a further decline in GFR in hyperfiltrating patients; whilst in normo-filtrators it remains stable. Regardless, hyperfiltration persists in about onethird of the patient population compared to agematched controls. 31 Parving's group also demonstrated hyperfiltration in microalbuminuric compared to normoalbuminuric type 2 diabetic patients and non-diabetic controls (GFR 117 ± 24 vs 99 ± 15 vs 98 ± 21 ml min −1 1.73 m −2 respectively). 32 Among Pima Indians in America, a group with a high incidence of type 2 diabetes associated with the highest reported incidence of diabetic renal disease, and in whom details of the onset and duration of diabetes are known with greater certainty, several studies have been reported. 28, 33 These studies do confirm that the GFR is often elevated; both in those with newly diagnosed disease and in those with long-standing diabetes, and remains so while normo-or microalbuminuria persists. It declines progressively after the development of macroalbuminuria. However, the baseline GFR in these patients predicted neither increasing UAER nor declining GFR during 4 years of follow-up suggesting that hyperfiltration itself is not the principal factor in the development or progression of nephropathy. Higher UAER at baseline, however, did predict increasing albuminuria, and in patients with macroalbuminuria, declines in the GFR; these findings suggest that enhanced protein flux across the glomerular capillary wall contribute to progressive glomerular damage. 33 As in type 1 patients, GFR remains stable up to and possibly during the phase of microalbuminuria, or until hypertension intervenes or persistent proteinuria develops. The rates of decline in GFR in type 2 patients with established nephropathy again are highly variable from individual to individual (4-22 ml/min/year), but overall, may not be substantially different from type 1 patients.
Microalbuminuria
Definition and screening
Measurement of UAER was introduced about 35 years ago, using radioimmunoassays. 34 The clinical significance of microalbuminuria as a predictor of overt nephropathy, however, only became apparent in the early 1980s. Microalbuminuria represents an early clinically detectable phase of diabetic nephropathy with a high predictive value for subsequent progression to overt nephropathy, particularly in type 1 diabetic patients. Several prospective studies have reported that approximately 50-80% of type 1 diabetic patients with persistent microalbuminuria will develop overt nephropathy over 10-15 years. [35] [36] [37] In type 2 patients, albuminuria is more heterogeneous and can develop as a consequence of hypertension, cardiovascular disease, diabetic or non-diabetic renal disease. Therefore, microalbuminuria in type 2 patients predicts the onset of nephropathy in about 20-40% of cases, its predictive value being less constant than in type 1 patients. 38 Persistent microalbuminuria is now widely accepted as a simple and sensitive procedure for early detection of diabetic patients at high risk of developing renal disease. 3 The concept of microalbuminuria is not complicated but reflects the insensitivity of the oldfashioned urine dipstick test to detect low levels of elevated UAER. Two approaches have been used in the definition of microalbuminuria. The first approach is based on the normal range of UAER in normal persons as compared to the level where the dipstick tests or other similar procedures become positive. When the normal excretion rate in a healthy population, as seen in almost all the published studies, is between 2-20 g/min (with a mean of 7 g/min) and the dip-stick positive level around 150-200 g/min, it is hardly surprising that the excretion rates between these two ranges (ie, g/min) cannot be detected by the conventional test strip. Therefore, a level between 20-200 g/min in the presence of a normal urine flow of 1 ml/min could be used to define microalbuminuria. Another approach would be to consider the range that is predictive of late nephropathy. In fact, the two approaches almost coincide and have resulted in the widely accepted European standard definition of microalbuminuria ( Table 3 ). The lower range predictive of diabetic nephropathy varies between 15-30 g/min. 35, 36 Based upon these figures from previous studies, a lower range of 20 g/min has been proposed with an upper level of 200 g/min. 39 The UAER is known to increase with strenuous physical exercise, excess protein intake, fluid loading, urinary tract infection, pregnancy, uncontrolled severe essential hypertension and cardiac failure. Urine albumin excretion is on average 25% higher during the day than overnight with a 40% day-today variation. For this reason 24-h urinary protein excretion was traditionally used to measure microalbuminuria. Due to problems in adequate collection 'timed-overnight collections' have been used. However, recently more efficient and less cumbersome methods to quantitate albuminuria have been utilised.
Alternative screening techniques
To screen large numbers, measurement of albumin/creatinine ratio assessed as milligrams of albumin per gram creatinine (ACR) in an early morning urine sample is more practicable than collecting timed urine samples on the unselected diabetic population. 40 In a mixed group of diabetics an ACR Ͼ2 predicts an UAER Ͼ30 g/min with a sensitivity of 96% and a specificity of 99.7%. In females ACR tends to be slightly higher than in males. Generally, a cut-off for microalbuminuria is often taken as an ACR over 3.5 for women and 2.5 for men.
Screening plan
For early detection of diabetic nephropathy and the establishment of a successful prevention programme several screening recommendations have been published over the last few years. [41] [42] [43] [44] [45] Differences between these recommendations have been discussed and the consensus was published recently by Mogensen and colleagues. 3 It is generally recommended that all post-pubertal type 1 diabetic patients with a disease duration of Ͼ5 years, and all Figure 2 ).
Risk factors for development and progression of microalbuminuria
Epidemiological studies have identified several putative risk factors for the development and progression of microalbuminuria in both type 1 and type 2 diabetes. These include male sex, age at diagnosis and duration of diabetes, genetic predisposition (ie, certain ethnic conditions, familial clus- Journal of Human Hypertension tering and ACE ID polymorphism), initial level of UAER, poor glycaemic control, mean arterial blood pressure Ͼ94 mm Hg, presence of retinopathy, smoking and hyperlipidaemia 46 (Table 4) .
Age, gender and duration of diabetes
The prevalence of microalbuminuria in type 1 diabetic patients is approximately 20%. 25 , 47 The duration of diabetes for patients with microalbuminuria is usually between 5-20 years, rarely being detected with disease duration of less than 5 years. The incidence of diabetic nephropathy, and the prevalence of microalbuminuria, is higher in those diagnosed under 20 years of age. The highest long-term incidence of nephropathy is found in those who develop type 1 diabetes between the age of 11 and 20 years. A disproportionate increase in renal hypertrophy during the phase of puberty has recently been noted. 48 The full effect of age on the evolution of renal disease is unclear; but the pre-puberty duration of diabetes appears not to contribute. Regardless, raised UAERs have been reported pre-puberty, including patients whose diabetes is of Ͻ5 years duration. 49 Females have a 1.5-fold excess incidence of type 1 diabetes when compared to males, but males have a higher risk of developing diabetic nephropathy, with a male to female ratio of 1.7 to 1. Over 40 years of age the cumulative incidence of nephropathy is 46% in males and 32% in female subjects. The male to female incidence ratio for ESRD is 1.1. This sex difference has, in part, been attributed to the effect of testosterone on the renal vasculature. In a population of patients with newly diagnosed type 2 diabetes UAERs are on average 2-3 times higher than age-matched controls. Although there is a lower correlation with disease duration than in type 1 dia- betes, possibly as a consequence of delayed diagnosis following the onset of diabetes in type 2 patients, it should come as no surprise that the longer the duration of diabetes in a patient, the greater the risk of developing nephropathy. The prevalence of microalbuminuria at diagnosis is 5-20%, though there is an initial decrease in UAER with treatment of diabetes. Cross-sectional studies of type 2 patients show a 15-60% prevalence of microalbuminuria depending on the racial origin of the patients. Pima Indians in America and IndoAsians in the UK have a particularly high incidence of microalbuminuria. 50 In type 2 diabetes, there is also a male excess risk for nephropathy, with a male to female ratio as high as 5:1 in some studies. Some of this gender-specific risk of developing nephropathy in these patients is only seen in certain ethnic groups. Patients diagnosed to have type 2 diabetes after the age of 50 have a higher prevalence of microalbuminuria than those diagnosed before the age of 40.
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Ethnicity
There is some variability in the reported cumulative incidences of microalbuminuria in both type 1 and type 2 diabetic patients and some of this variability, particularly in those with type 2 diabetes, is certainly due to ethnic factors. 50, 52 In European patients with diabetes the cumulative incidence of nephropathy is approximately 20% and 40% after 20 and 40 years of diabetes respectively. Studies in the Pima Indians and Japanese patients reported higher figures (50% at 20 years).
Genetic susceptibility and angiotensin-converting enzyme (ACE) gene polymorphism
The fact that despite poor glycaemic control (present in earlier epidemiological studies) only a minority of patients develops diabetic nephropathy indicates that genetic susceptibility is probably important. Seaquist et al 53 compared two cohorts of families with sib-pairs having type 1 diabetes, one in which there was no evidence of nephropathy in the proband (as defined by an UAER Ͻ45 mg/24 h), the other in whom at least one sibling had undergone renal transplantation for diabetic renal disease. It was observed that 82% of siblings of the proband with nephropathy had evidence of nephropathy compared to only 17% of the siblings of the proband free from nephropathy. Furthermore, among Pima Indians with type 2 diabetes, proteinuria was found to be three times more common in diabetic offspring whose parents both had proteinuria (45.9%) compared to offspring neither of whose parents had nephropathy (14.3%). 13 Increased synthesis of angiotensin II may play a role in the initiation and progression of diabetic nephropathy by affecting haemodynamic mechanisms and promoting growth of glomerular cells. 54 Recently it has been shown that an insertion/deletion (I/D) polymorphism of the ACE gene (ACE/ID) is strongly associated with the level of circulating ACE and increased risk of coronary heart disease in non-diabetic patients. 55 56 Several studies have reported an accelerated course of diabetic nephropathy and a reduction in the beneficial effects of therapy with ACE inhibitor in patients homozygous for the DD allele as reviewed by Parving. 46 Thus, the ACE gene has been proposed as a candidate gene for diabetic nephropathy on the basis of the above observations.
Normo-or microalbuminuria
A high UAER within the normal range (ie, Ͼ10 g/min) was found to be the most important risk factor for later development of incipient and overt nephropathy, both in type 1 diabetic patients 57, 58 and type 2 patients. 59, 60 This may suggest that even low rates of urinary albumin excretion reflect the pathological process leading to diabetic nephropathy. The initial level of UAER and the rate of annual increase in the urinary albumin excretion are also important risk factors for the progression of persistent microalbuminuria to overt nephropathy (higher risk for progression in those with a UAER Ͼ50 g/min).
A recent study from Denmark reported that while only 2% (95% confidence interval (CI), 0-6%) of normoalbuminuric normotensive type 1 diabetic patients develop nephropathy over a 5-year followup period, 19% (CI 12-27%) of normotensive patients with persistent micro-albuminuria will become nephropathic, 48% (CI 38-57%) will remain with microalbuminuria and 33% (CI 24 -42%) will become normoalbuminuric. 61 The authors concluded that microalbuminuria is a strong predictor of progression to overt nephropathy only in those patients with an annual increase in UAER of у5% and recommended the annual increase in UAER as a more specific method of identifying patients who will develop overt diabetic nephropathy.
Glycaemic control
Many studies have quite convincingly demonstrated that improved glycaemic control (ie, glycated haemoglobin (HbA1c) level of Ͻ7.5%) reduces the risk of developing microalbuminuria. Furthermore, in nearly all these studies, those patients who developed microalbuminuria or progressed from micro to macroalbuminuria had higher HbA1c levels.
In the large Diabetes Control and Complications Study (DCCT), intensive therapy of type 1 patients (HbA1c of 7.1% vs 9.0% in the conventional group over 9 years duration) was shown to delay the onset and slow the progression of microvascular complications, including nephropathy. In the primary prevention cohort (diabetes duration Ͻ5 years, no retinopathy and UAER Ͻ28 g/min), intensive treatment reduced significantly the mean adjusted risk of the cumulative incidence of microalbuminuria (UAER у28 g/min) by 34% (95% CI 2-56%; P = 0.04). In the secondary prevention cohort (diabetes Journal of Human Hypertension duration 1-15 years, minimal to moderate retinopathy and UAER Ͻ28 g/min) the risk of developing microalbuminuria was reduced significantly by 43% (CI 21-58%; P Ͻ 0.0001) and the risk of clinical albuminuria (UAER у208 g/min) by 56% (CI 18-76%; P Ͻ 0.01). 62 As to the impact of intensive glycaemic control compared to conventional control on progression and regression of microalbuminuria in type 1 diabetes (secondary prevention), the evidence is less strong with some studies reporting a significantly beneficial effect, whilst others have demonstrated no effect on increasing UAER in microalbuminuric patients. Similar to type 1 diabetes, intensive glycaemic control in newly diagnosed type 2 diabetic patients (an HbA1c level of 7%) significantly reduced the rate of progression from normoalbuminuria to microalbuminuria, as shown in the large United Kingdom Prospective Diabetes Study. 63 However, there was also no significant reduction in the risk of progression of microalbuminuria to proteinuria with intensive blood glucose control.
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Systemic and glomerular hypertension
An increase in arterial blood pressure is an early and frequent phenomenon in diabetic nephropathy. 46, 64 Diabetic patients with nephropathy have an 80% prevalence of hypertension (blood pressure Ͼ140/90 mm Hg) compared to 40% of those with microalbuminuria and 20% of those with normoalbuminuria. Once UAER has increased into the microalbuminuric range, blood pressure rises by an average of 2-3 mm Hg a year, and this is commonly associated with an impairment of the physiological 'nocturnal' dipping.
A significant increase in extracellular fluid volume due to increased sodium retention may contribute to the rise in blood pressure. Several studies suggest that elevated systemic blood pressure is a risk factor for the development and progression of microalbuminuria. [57] [58] [59] Indeed, a mean arterial pressure of Ͼ94 mm Hg predicts the progression of microalbuminuria more strongly than blood glucose levels. Evidence from animal models show that systemic hypertension leads to glomerular hyperperfusion and intraglomerular hypertension, which plays an important role in the initiation and progression of diabetic glomerulopathy. 65, 66 Recent treatment trials with blood pressure lowering drugs have also confirmed this concept as discussed below.
Smoking
The adverse effects of smoking on diabetic renal disease are well established but not widely appreciated. Diabetic patients who smoke have a greater risk of developing microalbuminuria than patients who do not smoke, and their rate of progression to ESRD is greater. 67 At least among patients with type 1 diabetes, there is also convincing evidence that the loss of renal function is slower in those who stopped smoking. 68 However, even in patients with type 2 diabetes stopping smoking is important, as this will reduce their high cardiovascular risk.
Hyperlipidaemia
In addition to the well-established importance of high serum cholesterol levels in the pathogenesis of arteriosclerosis, some studies have shown that hyperlipidaemia is an independent risk factor for the development of microalbuminuria, both in patients with type 1 57 and type 2 diabetes. 66 However, small double-blind randomised placebo controlled studies with statins in hypercholesterolaemic type 1 69 and type 2 70 patients with elevated UAER have failed to show a beneficial effect on albuminuria and rate of decline in GFR. Large controlled clinical trials examining the effects of lipid-lowering strategies on progression of diabetic and non-diabetic renal disease have, however, not been carried out. Despite the lack of demonstrable renal protective effect, lipid lowering in diabetic patients result in a significant risk reduction of major cardiovascular events that far exceeds the effects of such intervention in non-diabetic subjects. Their being initially at a higher risk to develop those events than their non-diabetic counterparts creates this difference in risk reduction, in favour of the diabetic patients.
Diagnosis of diabetic nephropathy
The majority of diabetic patients with proteinuria and retinopathy will have diabetic nephropathy. With prolonged disease duration most patients with type 1 diabetes develop typical histological lesions of diabetic glomerulosclerosis, although only onethird develop clinical overt nephropathy. About a third of type 2 diabetic patients with proteinuria will demonstrate the classical diabetic renal changes the rest will have a mixed picture of diabetic and non-diabetic renal changes. 71 Non-diabetic renal disease superimposed on diabetic glomerulopathy occurs more frequently in type 2 than in type 1 patients. In type 1 diabetes proteinuria develops in only 4% of patients within 10 years of diagnosis and this should raise the suspicion of other renal disease. Eight percent of type 2 diabetic patients have proteinuria at diagnosis, making duration of known diabetes of little value in elucidating the cause of renal pathology.
Retinopathy and overt diabetic nephropathy has a concordance rate of 85-99% in type 1 patients and 63% in type 2 patients, making the absence of retinopathy a strong indication for renal biopsy, particularly in type 1 patients. In a series of 136 consecutive biopsies on type 1 and type 2 patients a 66% incidence of haematuria was noted. Other studies have shown 69% of type 1 patients with proteinuria and haematuria to have concomitant nondiabetic renal disease. Red cell casts have only been found in 4% of biopsy proven diabetic nephropathy. There is an increased incidence of renal papillary necrosis and tuberculosis in diabetes and in the presence of modest proteinuria these should be considered. In type 2 patients, especially those with peripheral vascular disease, it is important to consider the diagnosis of renal artery stenosis. Overall the threshold for renal biopsy and further investigations should be lower in type 2 than type 1 patients (Tables 5 and 6 ).
Prevention and treatment of diabetic nephropathy
The available treatment strategies include: primary prevention (ie, treatment modalities applied to any normoalbuminuric diabetic patient at risk); secondary prevention (ie, treatment modalities applied to a diabetic patient at high risk (eg, with microalbuminuria) for development of diabetic nephropathy), and finally, 'Increasing Time To Dialysis' (ie, treatment of overt diabetic nephropathy). Interventions currently available include improved glycaemic control, antihypertensive agents, ACE inhibitors in normotensive patients, modification of dietary protein intake and others such as lipid-lowering agents. Whilst some small short-term studies have demonstrated a decline in UAER with reduction of dietary protein intake and lipid-lowering agents, longer large-scale studies are not available for these interventions to become established reno-protective treatments in clinical practice. Therefore, we shall concentrate on the role of optimum glycaemic control, tight blood pressure control and early use of ACE inhibitors as the most important modalities for the prevention and treatment of diabetic nephropathy. In addition to reno-protective strategies in diabetic patients, great attention has to be directed towards assessment of cardiovascular risk factors and their aggressive management, particularly in type 2 patients, as the majority of these patients have a high cardiovascular risk profile and will die prematurely from coronary heart disease and stroke.
Primary preventive strategies
The available evidence suggest that poor glycaemic control, high normal UAER and elevated blood pressure are the most important modifiable risk factors to predict progression from normoalbuminuria to microalbuminuria.
Glycaemic control
Optimum glycaemic control (HbA1c level of р7%) in patients with type 1 and type 2 diabetes can reduce the risk of development of microalbuminuria (primary prevention). In type 1 diabetes the level of glycaemic control seems to be the strongest modifiable risk factor influencing the transition from normoalbuminuria to microalbuminuria. A recent metaanalysis of seven randomised studies (total no. patients = 266) comparing the effects of intensive with conventional glycaemic control on risk of nephropathy progression in normo-and microalbumiuric patients showed that the risk of nephropathy progression, as defined by an increment in UAER, was decreased with intensified treatment (odds ratio 0.34 (0.20-0.58)). Most (approximately 80%) of the patients had normoalbuminuria but microalbuminuric patients were enrolled in five out of the seven studies. 72 The large Diabetes Control and Complications Trial (DCCT) study conclusively demonstrated that intensive therapy of type 1 diabetes (HbA1c of 7.1% vs 9.0% in the conventional group over 9 years duration) reduces the occurrence of microvascular complications. 62 In the primary prevention cohort (diabetes duration Ͻ5 years, no retinopathy and UAER Ͻ28 g/min), intensive treatment reduced significantly the mean adjusted risk of the cumulative incidence of microalbuminuria (UAER у28 g/min) by 34% (95% CI 2-56%; P = 0.04). In the secondary prevention cohort (diabetes duration 1-15 years, minimal to moderate retinopathy and UAER Ͻ28 g/min) the risk of developing microalbuminuria was reduced significantly by 43% (95% CI 21-58%; P Ͻ 0.0001) and the risk of clinical albuminuria (UAER у208 g/min) by 56% (95% CI 18-76%; P Ͻ 0.01). Despite these significant benefits of intensive glycaemic control, which was attained with extensive support from a multi-disciplinary diabetes team and at the expense of an increased incidence of hypoglycaemia, the study also showed that 16% of patients in the intensive therapy group with normoalbuminuria developed microalbuminuria suggesting that additional treatment modalities are needed in order to avoid or significantly reduce the burden of diabetic nephropathy.
In type 2 diabetes, the results of the large United Kingdom Prospective Diabetes Study have recently been reported. 63 This study has shown that intensive glycaemic control (HbA1c level of 7.0% vs 7.9% in the conventional control) in a total of 3867 patients Journal of Human Hypertension followed for over 10 years resulted in a significant reduction of 25% of microvascular end-points, most of which was due to fewer patients requiring photocoagulation. There was also a significant reduction in the development of microalbuminuria (23% vs 34.2% with a relative risk reduction of 33%).
In practice, optimum glycaemic control is demanding, difficult to achieve and frequently associated with problems (hypoglycaemia and weight gain). Thus, a target glycated haemoglobin value should be selected for each individual patient that provides an appropriate balance between risk and benefit.
Achievement of lower blood pressure levels
The results of the United Kingdom Prospective Diabetes Study (UKPDS) trial demonstrate that a lower blood pressure, 144/82 mm Hg vs 154/87 mm Hg reduces the risk for diabetes related end-points, including retinopathy, stroke, heart failure and diabetes related deaths in type 2 diabetic patients. At 6 years of follow-up tight blood pressure control significantly reduced the risk of microalbuminuria (29% risk reduction, P = 0.009) with a strong trend for reduction in overt proteinuria (39% risk reduction, P = 0.061). The reduction in risk for both microalbuminuria and overt proteinuria at 9 years of follow-up was not significant. 73 Interestingly, the study also demonstrated that both captopril and atenolol were equally effective in combination with other agents in reducing cardiovascular events.
In addition to the UKPDS, a series of other recently reported antihypertensive trials (including many type 2 diabetic patients) has shown similar results. These include the Systolic Hypertension in the Elderly Program (SHEP) study (low doses of diuretic-based regime, with beta-blockers and reserpine as reserves), the Hypertension Optimal Treatment (HOT) trial (a calcium-channel blocker, with various combinations) and the Syst-Eur Study (a calcium-channel blocker, with ACE inhibitors and diuretics as reserves). 74 -76 The above results have invited various organisations, including the WHO/International society of hypertension, to review their guidelines for blood pressure control and resulted in the general agreement that the target blood pressure level in all diabetic patients should be Ͻ130/85 mm Hg if well tolerated. 77 More recently the Canadian Hypertension Society and the National Kidney Foundation in the United States declared a goal of р130/80 mm Hg to reduce both cardiovascular (CV) and renal consequences of diabetes. 78, 79 Thus, the role of aggressive antihypertensive therapy in diabetic hypertensive patients is all-available resources should be used to implement the above recommendations. Until further evidence is provided from the ongoing large clinical trials regarding the true differences between different antihypertensive classes as far as clinical end-points are concerned; ACE inhibitors, low-dose diuretics, selective ␤-blockers and long-acting calcium channel blockers should be considered as suitable agents to use in some combination to achieve the blood pressure goal and subsequently reduce CV risk. However, it
Journal of Human Hypertension should be noted that ACE inhibitors are the most appropriate first-line agents since they are better tolerated than the other agents. Thus, the blood pressure goal can be achieved with these agents with the fewest possible side effects.
ACE inhibitors and primary prevention of nephropathy
Because of the well-established beneficial effects of ACE inhibitors in limiting the progression of renal disease in patients with microalbuminuria that will be discussed below, it would be reasonable to test whether the use of ACE inhibitors may be beneficial in patients with normoalbuminuria. Recently the EUCLID study, using a randomised double-blind placebo controlled design, evaluated the effect of treatment with lisinopril vs placebo on the progression of albumin excretion rate in 440 normotensive normoalbuminuric patients with type 1 diabetes (baseline mean UAER 8.0 g/min) followed for 2 years. 80 The absolute treatment difference between the two groups at 2 years, in the absence of significant changes in blood pressure, was 1.0 g/min (12.7% (−2.9-26%), P = 0.1). This effect, although not statistically significant, may be of clinical importance in limiting the development of renal disease, and reducing the proportion of patients whom would ultimately require renal-replacement therapy. An interesting finding, which was found by stratified analysis by different baseline levels of UAER, was that the ACE inhibitor-induced lowering effect of UAER applied to all levels of albuminuria down to 5 g/min, below which no beneficial effect was detectable. This may help define, for the first time, the level of UAER above which treatment with ACE inhibitors might be considered in interventions of primary prevention. The study also showed a significant reduction in the progression of retinopathy, including progression to proliferative retinopathy.
Similar to type 1 diabetes, the results of a recent randomised placebo controlled trial (enalapril vs placebo) in 156 normotensive type 2 diabetic patients with normoalbuminuria (mean baseline UAER 11.6 mg/24 h which is equivalent to 8.0 g/min) followed up for 6 years have been reported. 81 Progression to microalbuminuria occurred in 6.5% of enalapril recipients and 19% of placebo recipients with a statistically significant absolute risk reduction of 12.5% for development of microalbuminuria. Enalapril also significantly attenuated the decline in renal function as measured by creatinine clearance (a mean decrease of 0.025 mL/s per year vs a mean decrease of 0.04 mL/s per year in the placebo recipients).
These encouraging results have led to the publication of several cost-effective analysis studies suggesting that routine treatment with ACE inhibitors in all or at least high-risk type 1 and type 2 diabetic patients is a simple strategy that could prove more effective and even cost saving than the currently recommended approach of screening for microalbuminuria. [82] [83] [84] Ideally, if patients at high risk for the development of diabetic nephropathy could be identified at the stage of normoalbuminuria and treated with routine ACE inhibitors, then this may prove the most beneficial preventive approach. It is possible that further research in molecular genetics will allow better definition of this high-risk group, which will both reduce the number of patients requiring routine drug therapy and improve the cost-effectiveness of such preventive strategies. Only then, can such primary reno-protective therapeutic modalities be translated to routine clinical practice.
The results of Heart Outcomes Prevention Evaluation (HOPE) study and Microalbuminuria , Cardiovascular, and Renal Outcomes (MICRO-HOPE) substudy have been reported. 85, 86 In this secondary prevention trial of cardiovascular events, 3577 patients with diabetes, mainly type 2, aged 55 years or older, who had a previous cardiovascular event or at least one other risk factor (hypertension, microalbuminuria, current smoking, total cholesterol Ͼ5.2 mmol/L or high-density lipoprotein (HDL) cholesterol р0.9 mmol/L) were randomised to ramipril 10 mg/day or placebo and followed for mean period of 4.5 years. Exclusion criteria included heart failure, low ejection fraction, clinical proteinuria and treatment with ACE inhibitors. Ramipril significantly lowered the risk of combined primary outcome of myocardial infarction, stroke or cardiovascular death by 25% (95% CI 12-36%; P = 0.0004), total mortality by 24% (95% CI 8-37%; P = 0.004), and overt nephropathy by 24% (95% CI 3-40%; P = 0.027). After adjustment for the small changes in systolic (2.4 mm Hg) and diastolic (1.0 mm Hg) blood pressure, ramipril still significantly lowered the combined primary outcome by 25%.
In patients without baseline microalbuminuria, the relative risk of developing microalbuminuria was non-significantly reduced by 9% (95% CI −4 to -20%; P = 0.17). Ramipril also significantly lowered the need for revascularisation by 17%, development of any heart failure by 20%, transient ischaemic attacks by 26%, and risk of a combined microvascular outcome of overt nephropathy, dialysis, or laser therapy by 16%. 86 The observed benefits of ramipril were thought to be due largely to a protective effect of ACE inhibitors on the arterial wall that may be mediated by the lowering of angiotensin II concentrations and the increasing of bradykinin concentrations. When the major cardiovascular and microvascular events are taken into account, 15 high-risk patients with diabetes would have to be treated with ramipril for a median of 4.5 years to prevent one individual from having a myocardial infarction, stroke, cardiovascular death, admission to hospital for heart failure, a revascularisation procedure, development of overt nephropathy, laser therapy for retinopathy, or renal dialysis.
The HOPE findings have considerable implications for clinical practice, since they indicate that virtually all patients with a cardiovascular disease, not just those who have had an acute myocardial infarction or who have heart failure, may now benefit from ACE inhibition. Diabetic patients with no history of cardiovascular disease and non-diabetic patients with established heart disease have similar rates of mortality from coronary heart disease. 87 Thus, the message from the HOPE study is that the addition of ACE inhibitors to other proven cardiovascular prevention strategies such as tight blood pressure and glycaemic control, lipid lowering, stopping smoking, and aspirin should further lower the cardiovascular and microvascular events in diabetic patients with high cardiovascular risk profile.
Clinicians are invited to use more of ACE inhibitors in the diabetic hypertensive population and in the normotensive microalbuminuric patients, because these agents have been recommended as one of the first-line antihypertensive therapies, and have a proven reno-protective effect, even in normotensive patients with microalbuminuria.
Secondary prevention of nephropathy
The levels of urinary albumin excretion, arterial blood pressure, glycaemic control and serum cholesterol are the most important modifiable risk factors found in trials of secondary prevention in patients with persistent microalbuminuria.
Glycaemic control
Once the stage of microalbuminuria is reached there is little evidence for an impact of good glycaemic control on the progression of microalbuminuria to macroalbuminuria (secondary prevention) with some, but not all, studies showing a significantly beneficial effect. 72 Indeed from a therapeutic point of view, preventing the progression of renal disease in patients with microalbuminuria is more obtainable by non-glycaemic intervention such as the early use of ACE inhibitors. 62, 88 Analysis of all type 1 diabetic patients enrolled in the reported five randomised intensive diabetic treatment trials showed no statistically significant impact on the progression to overt nephropathy. 72 In type 2 patients intensive glycaemic control had no significant impact on reduction of progression of microalbuminuria to overt nephropathy in the large UKPDS study. 63 Only one small Japanese study showed some beneficial effects for intensive therapy compared to conventional therapy (HbA1c level of 7.1% vs 9.4%) and a valid evaluation cannot be made. However, the current guidelines recommend improved glycaemic control in all diabetic patients with microalbuminuria, as this will reduce the risk of development and progression of retinopathy.
Antihypertensive therapy
The definition of hypertension in microalbuminuric patients is not universally agreed upon, but generally a blood pressure level of у130/85 mm Hg is considered elevated. 77 Recently it has been recommended that intervention, initially non-pharmocological, should start when blood pressure is у140/90 mm Hg, with the aim of reducing blood pressure to Ͻ130/85 mm Hg, and if that is well tolerated a further careful lowering of blood pressure to 120/80 mm Hg is suggested. 89 Meta-analyses by Kasiske et al 90 and Weidmann et al 91 including short-
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and long-term studies of type 1 and type 2 diabetic patients with micro-and macroalbuminuria demonstrated an enhanced antiproteinuric effect of ACE inhibitors over ␤-blockers and diuretics. This effect appears to be independent of a reduction in blood pressure. With increasing reduction in blood pressure the difference between the agents was reduced. 91 In a recent meta-analysis by Maki et al 92 the effect on GFR was the same for different classes of antihypertensive agents, except for an increased loss in GFR with dihydropyridine calcium antagonists (such as nifedipine). 92 The relative efficacy of ACE inhibitors and certain subclasses of calcium channel blockers continue to provide one of the main controversies in the field of diabetic nephropathy. While preliminary findings from the Melbourne Diabetic Nephropathy Study Group revealed that prevention of macroalbuminuria does not occur with nifedipine; 93 a recent Italian study has suggested that nifedipine can delay the onset of overt nephropathy in type 1 normotensive diabetic patients with microalbuminuria. 94 Furthermore, a number of other studies in type 2 diabetic patients with microalbuminuria suggest that the reno-protective effects of other calcium channel blockers may be comparable to ACE inhibitors. 95, 96 ACE inhibitors appear to be more effective than calcium channel blockers in reducing the progression of microalbuminuria (a surrogate end-point of renal disease progression). A large, randomised, controlled, comparative clinical trial lasting at least for 3-5 years is required to enable valid information to be obtained on kidney function and structure (principle end-points). Until such results become available, when treating hypertensive diabetic patients with microalbuminuria, it is reasonable to use ACE inhibitors as the first choice, combined when necessary with a long-acting calcium channel blocker and a diuretic, to achieve the desirable blood pressure levels and reduction in progression of albuminuria, as well as prevention of cardiovascular events.
ACE inhibitors
Early treatment using ACE inhibitors normalises intra-glomerular pressure and prevents glomerulosclerosis and proteinuria in diabetic animals. 96, 97 Over recent years great interest has surrounded the use of ACE inhibitors in microalbuminuric patients with and without hypertension. Although diabetic patients with microalbuminuria have higher blood pressure levels than diabetes duration and agematched controls, these readings are still usually in the conventionally defined normal range. In these normotensive type 1 diabetic patients several randomised, placebo-controlled studies, the longest of which lasted for 8 years, have reported a significant reduction in the risk of progression to overt nephropathy, associated with a slower rate of decline in the GFR. 78, 88, [98] [99] [100] [101] A recent combined analysis of the European and North American studies of 2 years therapy with captopril (50 mg b.d.) vs placebo in 116 vs 119 normotensive type 1 diabetic patients (blood pressure Ͻ140/90 m Hg in the American and Ͻ145/90 aged Ͻ35 years, Ͻ160/95 aged Ͼ35 years in the European patients) showed a 62.9% risk reduction (8 vs 25 patients) for the development of overt nephropathy in the actively treated group (P = 0.017). 102 In the longest study reported to date, the percentage of patients progressing to nephropathy was 40% (9/23) in the control group and 10% (2/21) in the captopril treated group (75% relative risk reduction, P Ͻ 0.02). The fall in the GFR was 12.2 ml/min in the control group and 1.4 ml/min in the captopril group (P = 0.06). 103 Thus, this Danish study provided the first long-term evidence that early treatment with ACE inhibitors in such normotensive type 1 diabetic patients with microalbuminuria postpones and, in some patients, may prevent the development of overt nephropathy.
Although most type 2 diabetic patients with microalbuminuria are hypertensive and will benefit from tight blood pressure control (target blood presure levels of Ͻ130/85 mm Hg) that will help to slow down the progression to overt nephropathy and also reduce the overall high cardiovascular risk profile, a significant proportion will be normotensive by conventional criteria, particularly in the Asian population. In these normotensive microalbuminuric type 2 diabetic patients the same effect of ACE inhibitors on the course of microalbuminuria in normotensive type 1 patients has also been found, with three important randomised placebo-controlled studies showing a significant reduction in progression to macroalbuminuria, and some also confirming a modest renal protective effects (stabilization of creatinine and slowing down the rate of decline in creatinine clearance) in patients followed for 4-7 years (secondary prevention). [104] [105] [106] In the first study which followed 94 patients for 5 years randomly allocated to enalapril 10 mg or placebo, albuminuria remained stable in the enalapril group (UAER was mean [s.d.] 143 [64] mg/24 h at baseline vs 140 [134] mg/24 h after 5 years), while in the placebo group, albuminuria has increased from 123 [58] mg/24 h to 310 [167] mg/24 h after 5 years (P Ͻ 0.05). Twelve percent (6/49) of patients in the enalapril group developed overt nephropathy compared to 42% (19/45) of patients in the placebo group with an absolute risk reduction of 30% (95% CI 15-45%; P Ͻ 0.001). Furthermore, renal function (expressed as mean reciprocal creatinine) remained stable in the enalapril group and declined by 13% in the placebo group (P Ͻ 0.05). 104 Although the evaluation of renal function, assessed by 100/serum creatinine, was rather crude, this was the first longterm study to demonstrate both an anti-proteinuric effect of an ACE inhibitor and preservation of renal function in normotensive type 2 diabetic patients with microalbuminuria. A follow-up report after 7 years of treatment confirmed the renoprotective effect of ACE inhibition in this cohort. 107 In a 4-year Japanese study, 62 patients with type 2 diabetes and microalbuminuria were randomised to either enalapril 5 mg or placebo. UAER was reduced from: mean [s. There were no significant changes in creatinine clearance, blood pressure and glycaemic control in either group during the study period. 105 Recently, similar effects on albuminuria after 5 years of ACE inhibitor therapy in a group of Indian normotensive type 2 diabetic patients with microalbuminuria have been reported. 106 Enalapril treatment was associated with a reduction in albuminuria whereas in the placebo group there was a progressive rise in UAER. In all the above studies, treatment with ACE inhibitors was well tolerated with less than 5% of patients having to discontinue therapy due to side effects and this number was not statistically different in those on placebo or active treatment.
Very recently, the effects of intensified multi-factorial treatment of type 2 diabetic patients with microalbuminuria have been evaluated in a 4-year open parallel trial. 108 Patients were allocated to either standard treatment (treatment goals included HbA1c level of Ͻ7.5%, blood pressure Ͻ160/95 mm Hg, total cholesterol Ͻ6.5, HDL-cholesterol Ͼ0.9, triglycerides Ͻ2.2 mmol/L) or intensive treatment (treatment was a stepwise implementation of behaviour modification and pharmacological therapy, and treatment goals included HbA1c level of Ͻ6.5%, blood pressure Ͻ140/85 mm Hg, total cholesterol Ͻ5.0, HDL-cholesterol Ͼ1.1, triglycerides Ͻ1.7 mmol/L, ACE inhibitor with captopril 50 mg b.d. irrespective of blood pressure, aspirin to patients with known ischaemic heart or peripheral vascular disease). Intensive multifactorial treatment significantly slowed the progression to nephropathy (8/73 patients developed overt nephropathy compared to 19/76 patients in the standard group) and progression of retinopathy and autonomic neuropathy (19/73 and 8/73 patients compared to 33/76 and 22/76 patients in the standard group). Thus, it appears that intensive treatment of type 2 diabetic patients with microalbuminuria is worthwhile to delay the progression of microvascular, and possibly prevent macrovascular, complications and is without severe side effects (Figure 3 ).
Increasing time to dialysis
Once nephropathy is present, eg, proteinuria Ͼ500 mg/day, blood pressure Ͼ130/85 mm Hg and serum creatinine Ͼ107 mmol/l (1.2 mg/dl) for women, 124 mmol/l (1.4 mg/dl) for men, the role of glucose control is relatively less important than blood pressure control for reducing CV events and slowing renal disease progression. 63, 109 Based on the recommendation of the most recent Consensus Report of the National Kidney Foundation to achieve blood pressure control, agents that lower both blood pressure and proteinuria are preferred over agents that only reduce blood pressure.
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Glycaemic control
For many years it was believed that intensive glycaemic control does not appear to have a significant effect on renal function once overt nephropathy is established. It has been suggested that by the time glomerular function has started to decline in diabetic nephropathy the process culminating in ESRD has become self-perpetuating and is little influenced by the degree of metabolic control. 110, 111 However, several studies of large numbers of type 1 diabetic patients have recently documented the important impact of glycaemic control on progression of diabetic nephropathy. 112, 113 These studies have demonstrated a greater rate of decline of GFR with poor glycaemic control, with the slowest rate of progression of nephropathy in those patients with a lower glycated haemoglobin (HbA1c level of Ͻ6.6%).
113 For people with type 2 diabetes, glucose control has also been shown to reduce CV events, but its impact is dwarfed by that of tight blood pressure control. 73 It is recommended, therefore, that every effort should be made to achieve the best possible glycaemic control in all patients with overt diabetic nephropathy as this will also help to prevent and/or delay the progression of other microvascular complications. Most oral hypoglycaemic agents, particularly chlorpropamide, glibenclamide, tolbutamide and metformin, are metabolised or cleared by the kidneys. They therefore accumulate in patients with renal failure, increasing the risks of hypoglycaemia and toxicity. Lactic acidosis, which is a serious problem, may occur with metformin in people with serum creatinine values of Ͼ132 mmol/l (1.5 mg/dl). With the development of the thiozolidinediones, such as rosiglitazone and pioglitazone, however, an alternative to metformin is now available. These
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Tight blood pressure control
It is well recognised that arterial hypertension is an early and frequent phenomenon in overt diabetic nephropathy, a state also characterised by a high prevalence of nocturnal hypertension (non-dipping, ie, absence of the physiological dipping in blood pressure at night). Several studies have confirmed that early and aggressive antihypertensive therapy in diabetic patients with overt nephropathy and hypertension will reduce the rate of decline in GFR, sometimes to less than one-fifth of pre-treatment values, with parallel reduction in proteinuria.
Protection of renal function is evident in those who demonstrate a decline in UAER. 114 -116 The most favourable results (in type 1 patients) suggest that progression from normal GFR to ESRD may be delayed by up to 30 years, rather than the average 7 years in inadequately treated patients. 113 Such studies have also helped to establish target blood pressure levels for patients with diabetic nephropathy (ie, below 130/80 or preferably 125/75 mm Hg if well tolerated), in order to attain maximum retardation of the decline in GFR. Retrospective studies in type 1 diabetic patients suggest a reduction in the cumulative death rate over the past 20 years of antihypertensive treatment, from 80% to less than 20% at 10 years of overt nephropathy. Thus, the role of aggressive antihypertensive therapy in patients with diabetic nephropathy and hypertension has been established and all the available major antihypertensive agents should be considered to achieve the recommended target blood pressure levels. Recent studies have, therefore, attempted to address the issue of specific reno-protective effects of particular groups of agents, particularly ACE inhibitors.
ACE inhibitors
ACE inhibitors are now widely used as first-line agents for treating diabetic nephropathy. As well as lowering systemic blood pressure, these drugs can reduce intraglomerular pressure by preferentially relaxing efferent glomerular arterioles, and may interfere with trophic properties of angiotensin II to promote cellular and glomerular hypertrophy or diminish the accumulation of mesangial matrix. Either of these processes could be an important initial step leading to glomerular scarring. These effects of ACE inhibitors on glomerular haemodynamics or glomerular barrier function could also help to explain their possible reno-protective effect (ie, a beneficial effect on kidney function above and beyond that expected from the blood pressure-lowering effect alone); which is still a controversial issue. Nonetheless, ACE inhibitors are highly effective at reducing both blood pressure and proteinuria, with minimal side effects. On starting therapy with ACE inhibitors, 'first-dose' hypotension may occur especially in patients with autonomic neuropathy or those overtreated with diuretics. Care must also be taken, especially in those with widespread vascular disease, as the coincidental presence of renal artery stenosis may result in an acute decline in renal function. Hyperkalaemia is also more common in those with overt diabetic nephropathy, and regular monitoring of renal function and electrolytes is recommended.
The first randomised open-labelled study dealing with ACE inhibitors in normotensive type 1 patients with overt nephropathy was reported in 1989. Treatment with captopril for 1 year arrested the progressive rise in albuminuria compared to no treatment. 117 Similarly, an antihypertensive treatment with enalapril for 2.2 years was shown to reduce proteinuria in type 1 patients with overt nephropathy more than an equally effective antihypertensive treatment with metoprolol. 118 Indeed, this was the first prospective, randomised study to suggest a specific reno-protective effect in diabetic nephropathy.
In a large prospective, randomised study, 409 type 1 diabetic patients with overt nephropathy in whom serum creatinine was у221 mol/L were followed up for up to 4 years. 119 Two hundred and seven patients received captopril 25 mg t.i.d. and 202 placebo, in addition to traditional antihypertensive treatments to achieve appropriate blood pressure control (140/90 mm Hg). Captopril treatment resulted in halving of the risk of doubling serum creatinine concentration and also progression to renal support therapy (dialysis or transplantation). The beneficial effects of additional captopril treatment were concentrated in those patients with baseline serum creatinine concentrations above 133 mol/L.
Furthermore, and of greater significance, was the prospective and conclusive finding in this study of a reduction in mortality in type 1 patients with overt nephropathy receiving ACE inhibitors therapy.
These beneficial effects of captopril therapy were not explained by the small differences in the level of blood pressure control between the two groups. This study, therefore, supports a specific reno-protective effect for ACE inhibitors in overt diabetic nephropathy. Recently, another randomised study reported that the beneficial effects of captopril in arresting the progressive rise in arterial blood pressure and albuminuria in normotensive type 1 patients with diabetic nephropathy is long lasting (a total of 32 patients, 15 treated with captopril and 17 with placebo, were followed for 8 years). 120 Thus, therapy with ACE inhibitors should be considered in all type 1 patients with overt diabetic nephropathy, whether those with hypertension or 'normotension'.
As in type 1 patients, antihypertensive therapy is of paramount importance in protecting renal function in type 2 patients with overt diabetic nephropathy and hypertension. However, the specific roles of differing classes of antihypertensive agents have not been clearly established for type 2 patients. In a prospective self-controlled study of type 2 patients with early overt diabetic nephropathy, mild to moderate hypertension and retinopathy, Vora et al 121 first demonstrated that administration of captopril resulted in control of hypertension and reduction in albuminuria with no significant changes in renal haemodynamics. Analysis of the reported studies dealing with the effects of antihypertensive treatment with or without ACE inhibitors on albuminuria and on GFR in hypertensive type 2 patients with overt diabetic nephropathy demonstrates a greater antiproteinuric effect of ACE inhibtors compared with regimen not including ACE inhibitors. [122] [123] [124] [125] Only one study reported a significant difference in rate of decline in GFR in patients with and without ACE inhibitor therapy. 124 Currently, several large multinational, randomised-placebo controlled trials with selective angiotensin-II receptor blockers are ongoing in hypertensive type 2 diabetic patients with nephropathy, the results of which are eagerly awaited.
Few long-term studies with calcium-channel blockers (CCBs) have been carried out to assess their effects on progression of diabetic nephropathy, either alone or in combination with ACE inhibitors. Most studies suggest that the non-dihydropyridine CCBs (diltiazem-and verapamil-like agents), in general, appear to reduce proteinuria more effectively than the dihydropyridine agents, even in the presence of similar blood pressure control. 126, 127 Interestingly, it has been shown that combination therapy with an ACE inhibitor and a non-dihydropyridine CCB in lower doses, is more effective in reducing proteinuria and preventing progression of nephropathy than when used alone. 126 A very recent study in 50 normotensive type 1 diabetic patients with nephropathy (blood pressure 124 ± 12/74 ± 7 mm Hg, UAER median [range]: 102 g/min, diabetes duration 22 [4 -43] ) evalu- ated the impact of treatment with enalapril 10 mg daily vs nifedipine retard 20 mg daily vs placebo on renal structure and function. 128 After 3 years of follow-up enalapril resulted in a significant reduction in albuminuria but there was no effect of nifedipine or placebo. GFR declined at approximately 4 ml/min/year in all groups with no difference between those with micro-or macroalbuminuria. Blood pressure remained unchanged and there was no change in renal structure in all groups. This study suggests that ACE inhibition reduces UAER in normotensive type 1 diabetic patients with nephropathy but without effect on the underlying glomerulopathy. It also shows that normal blood pressure is associated with slow progression of nephropathy irrespective of treatment.
It should be stressed that the antiproteinuric effect of ACE inhibitors in patients with diabetic nephropathy varies considerably. Individual differences in the renin-angiotensin system due to genetic factors (ie, I/D polymorphism of the ACE gene) may influence this variation. Recently, the Euclid Study group showed that UAER was 57% lower on lisinopril in the II group, 19% lower in the ID group, and 19% higher in the DD group compared with placebo. 80 Five hundred and thirty normotensive type 1 diabetic patients with normo-or microalbuminuria participated in this randomised double-blind study lasting 2 years. Furthermore, the deletion polymorphism in the ACE gene reduces the long-term beneficial effect of ACE therapy on progression of diabetic nephropathy. 129, 130 These findings suggest that the DD genotype patient should possibly be offered more aggressive ACE inhibition or treatment with the new angiotensin-II receptor blockers in combination with non-dihydropyridine CCB (Table 7) .
Conclusions
Over the past two decades there have been major advances in our attempts to understand the risk factors for the development and progression of diabetic Journal of Human Hypertension renal dysfunction that resulted in better characterisation of the natural history of this serious complication in both types of diabetes. Effective antihypertensive treatment and aggressive management of cardiovascular risk factors helped to improve tremendously the prognosis of patients with overt diabetic nephropathy. We can now identify patients at high risk early and the challenge for the practising physician is to use the different modalities of treatment to prevent progression to overt nephropathy and reduce the associated high risk of cardiovascular morbidity and mortality.
